Montelukast Evolugen (Montelukast Sodium)

Montelukast sodium, the active ingredient in Montelukast Evolugen, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring maintenance therapy.

GNH USA supplies Montelukast Evolugen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Evolugen belongs to the leukotriene receptor antagonist class and is indicated for conditions involving airway inflammation and bronchoconstriction.

- Asthma: provides maintenance therapy that reduces the frequency of symptoms and exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Mood changes: including depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin reaction. - Allergic reactions: rash, itching or hives. - Bronchospasm: paradoxical worsening of breathing.

Before initiating therapy, consider the following safety measures.

- Pregnancy: Category B – use only if clearly needed. - Lactation: assess risk versus benefit for nursing mothers. - Hepatic impairment: monitor liver function periodically. - Drug hypersensitivity: avoid if known allergy to montelukast or excipients. - Enzyme inducers: be aware that concomitant phenobarbital or rifampin may reduce efficacy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; review patient medication lists regularly.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: strong enzyme inducers that can lower montelukast plasma levels. - Ketoconazole or other potent CYP3A4 inhibitors: may increase montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Beta‑agonists (e.g., albuterol): additive bronchodilatory effect, watch for excessive stimulation. - Aspirin/NSAIDs: may increase risk of bronchospasm in sensitive individuals.